Richard Hinds’ Post

COPD Management: Evidence Report on Ensifentrine 🌬️ Breathe easier with new COPD treatment insights! Discover how #Ensifentrine could improve life for millions. 🏥💡 Read our latest article on #COPDmanagement and learn about the potential of this innovative therapy as well as its cost-effectiveness. #RespiratoryHealth #PatientCare #HealthcareInnovation https://lnkd.in/dAqHd8x3

Study demonstrates the relevance of #physical activity for key #COPD outcome metrics and underpins the importance of physical activity for COPD self-management in everyday life Dove Medical Press https://lnkd.in/e_3hnz2u

Do you have any insights on this? A study on COPD that is focused on human factors and patient needs, with an aim to understand the challenges patients face in order to support the development of treatment. https://lnkd.in/eMWv8QRt #RespiratoryPC

5 things COPD patients want their doctors to know, according to real patients and caregivers https://lnkd.in/gdzRFyq3

Ema Rastoder har publiceret en artikel hos Copenhagen Respiratory Research COP RESP om koagulationen hos patienter med kronisk obstruktiv lungesygdom i rolig fase og i forbindelse med en forværring. Ema Rastoder has published an article with Copenhagen Respiratory Research COP RESP on coagulation patterns in patients with COPD during steady fase and in relation to an exacerbation. https://lnkd.in/eMnMbqis

https://lnkd.in/gUqtJfQf Can muscle wasting responsible for increase in grade of Dyspnoea in severe stage of COPD?

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory conditions. It is the third leading cause of death worldwide, according to the World Health Organization. COPD is not curable, but early detection is important to slow its progression. Symptoms can go unnoticed in the early stages though, and the American Lung Association suggests there have been potentially millions of underdiagnosed cases in the past.. We’re proud to be collaborating with Koye Pharmaceuticals Pvt Ltd on a program to create a novel vocal biomarker for COPD in India, where the disease is the second biggest cause of death [https://lnkd.in/e_9RB5cE]. By leveraging our clinically validated, voice-powered respiratory health tracking platform, Koye is able to develop solutions that will enable physicians to treat their patients’ COPD symptoms more effectively. Read More 👉 https://lnkd.in/djecyEF) #vocalbiomarkers #digitalhealth

🏔 Uncovering the Mysteries of COPD at High Altitudes 👟 Living with COPD comes with its own set of challenges, but when you add in altitude hypoxia, the game changes completely. At >2500 meters above sea level, COPD patients face a whole new level of physical fitness deterioration... Global initiatives for COPD emphasize the importance of personalized exercise programs for its treatment... But here's the twist: standard cardiopulmonary exercise tests (CPET) may prove inadequate for those living in high-altitude regions... Our recent case report delves into this issue. We followed a COPD patient residing at >2500 meters through different cardiopulmonary exercise test (CPET) protocols with a two-week gap until achieving our proposed CPET... 🏁 The goal? To establish a CPET protocol for COPD at high altitudes that allows for maximum thresholds of physical performance... 🔎 What did we discover? The minimum criteria set by the American Thoracic Society (ATS) were not met with conventional CPET protocols, and crucial cardiovascular, ventilatory, and metabolic maximals crucial for exercise prescription were not achieved. 📚 Our conclusion? It's time to adapt. CPET protocols for COPD patients need a high-altitude overhaul to truly achieve maximum thresholds... We present our proposed CPET protocol. Let's breathe new life into COPD treatment and tailor our approach to the air we breathe. #COPDInsights #HighAltitudeHealth #AdaptandThrive 🌬️🏔️ https://lnkd.in/eVZENsmD

The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort https://lnkd.in/ef5mFuFz?

I recently read an article on how the number of global COPD patients is projected to reach nearly 600 million by 2050. According to data from 2020, COPD impacted approximately 480 million people around the world, equating to 10.6% of the total population (and a whopping 16.8% of North Americans). These numbers are big, but they aren’t surprising to someone who works in the #copd space. In general, I believe there needs to be greater awareness of COPD – not only of the risk factors to help prevent the disease but also increased knowledge of symptoms so the condition can be managed better, earlier. If COPD rates continue to rise, it’s evident that a greater burden will be placed on patients, providers, and hospitals. Luckily, in the words of Dr. Diego Maselli Caceres, a thought leader in this area and nationally recognized pulmonologist at @UT Health in San Antonio, "There has never been a better time to be diagnosed with COPD." This is because of proven digital continuous monitoring platforms like Spire Health that can better serve this challenging patient population.  Check out the full @COPDNewsToday piece by Margarida Maia, PhD here: https://lnkd.in/eH3eN_Pd